Beta Bionics, Inc. (BBNX)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Beta Bionics, Inc. currently loses $73.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 27
in 2 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Beta Bionics beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported July 29, 2026, as revenue rose 37.8% to about $32.0 million, driven by its insulin-delivery systems lineup led by the iLet Bionic Pancreas platform. Revenue of $32.0 million topped the $31.5 million estimate, +2%, while EPS of -$0.53 topped the -$0.58 estimate by $0.05 (down from -$0.39 a year ago). Profitability tracked higher gross margin but remained loss-making at the operating line, with gross profit of roughly $18.9 million and gross margin at 59.0% alongside an operating loss of about $25.6 million and operating margin of -79.9%. Net income was -$23.4 million (down from -$16.9 million a year ago, -38.7%), and operating cash flow was negative at roughly $14.6 million. For the next period, consensus calls for EPS of -$0.55 on revenue of $35.0 million.
Next report — what to expect
Beta Bionics, Inc. (BBNX) is scheduled to report earnings on October 27, 2026. Wall Street’s next-period consensus calls for EPS of -$0.55 on revenue of $34.8 million. For trailing context, revenue grew +37.8% year over year last quarter. The company has beaten EPS in 6 of 8 most recent quarters.
About Beta Bionics, Inc.
Beta Bionics, Inc. develops insulin-delivery systems for people with diabetes who depend on insulin and trades on the NASDAQ under BBNX as a medical-device company in healthcare. Its products center on automated dosing platforms, and the company generated $100.3 million of revenue in FY2025.
Today's Snapshot
BBNX closed 0.9% lower at 19.16, in line with a weaker sector. Investors sought to lead a securities class action against Beta Bionics after substantial losses. BBNX reports earnings on 27 October.
Trading Volume
Below 10d avg (959.1K)
826.4K
vs S&P 500 Today
Moderate Underperformance
-0.41%
Updated: October 23, 2026 at 20:14 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$17.62 - $18.39Buy
- RSI (14)54.47Neutral
- Stochastic %K (14, 3, 3)86.60Sell
- MACD Level (12, 26)-0.26Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.